



First Patient treated with Pencil Beam Scanning at the Institute Curie Proton Therapy Center

Louvain-la-Neuve, Belgium, May 19 2017 - IBA, the world's leading provider of proton therapy solutions for the treatment of cancer, announces that the first patient has been treated with Pencil Beam Scanning (PBS) technology at the Institut Curie in Orsay.

Since its opening in 1991, more than 8 000 patients have been treated at the Institute Curie Proton Therapy Center. During this time, the Center has gradually upgraded its equipment to increase the number of indications that can be treated. Today, around fifty patients are treated every day in the three rooms available. The rooms include; one Gantry, one Fixed Beam and an Eye Line.

PBS is the latest addition to the IBA Proteus®PLUS solution in operation in Orsay. PBS enables the clinician to deliver Intensity Modulated Proton Therapy by accurately targeting the tumor with controlled dose intensity and precise spatial distribution. To date, more than 200.000 fractions have been delivered with IBA Pencil Beam Scanning equipment.

Dr Remi Dendale, Deputy Director of the Institute Curie Proton Therapy Center, commented: "We are very happy to upgrade our equipment with the latest technology available. This enables us to offer proton therapy to more patients by broadening the list of indications we can treat. Thanks to the excellent collaboration with IBA, our team has been able to implement this new feature with zero impact on our clinical operations."

Anne Peters, Executive Vice-President EMEA at IBA, added: "This is yet another example of our ability and commitment to upgrade all customers with our latest technological developments. Offering solutions that have clinical meaning and helping our customers in their daily lives is IBA's number one priority."



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About Institute Curie

The Institute Curie, a leading player in the fight against cancer, combines a leading French research center in oncology and a state-of-the-art hospital group that treat all types of cancer, including the rarest. Founded in 1909 by Marie Curie, the Institute Curie brings together more than 3,300 researchers, physicians and healthcare professionals around its three missions: care, research and teaching.

As a private foundation recognized for public utility, the Institute Curie is authorized to receive donations and bequests and can, thanks to the support of its donors, accelerate the discoveries and thus improve the treatment and the quality of life of the patients.

For more information, see www.curie.fr

**Proteus®PLUS is the brand name of Proteus®235.*



For further information, please contact:

IBA

Jana Kulhankova

Marketing Associate, Proton Therapy

Tel +32 10 203652

jana.kulhankova@iba-group.com

IBA

Thomas Ralet

Vice-President Corporate Communication

Tel +32 10 475890

communication@iba-group.com

Anne Peters

Vice-President EMEA-Latam-Russia

Tel +32 10 203 698

anne.peters@iba-group.com